Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- CSL Behring Seeks Approval of Human Prothrombin Complex
August 26, 2016
- Actemra Filed for Weekly Dosage for Inadequately Controlled RA
August 26, 2016
- Mitsubishi Tanabe Transitions from “Open Innovation” to “Open Shared” System: President
August 26, 2016
- Sizzling DOAC Market - 3: Dosage and Administration Vary by Product for PE/DVT Treatment
August 26, 2016
- Sizzling DOAC Market - 2: Makers Accumulating Data from Actual Clinical Settings to Support Proper Use
August 25, 2016
- Announcement: Real World Data Japan 2016 to Be Held at Westin Tokyo Hotel on October 18-19
August 25, 2016
- Sizzling DOAC Market - 1: Japan Sales Reaching 140 Billion Yen on 4-Way Fight
August 24, 2016
- Canaglu-Tenelia Combo Filed in Japan: Mitsubishi Tanabe
August 23, 2016
- GSK Paid 6.2 Billion Yen to Doctors, Medical Institutions in 2015
August 23, 2016
- New Treatment Options Arriving in Multiple Myeloma Arena
August 23, 2016
- Sales per Drug Rep Check in at 168 Million Yen in FY2015: Survey
August 22, 2016
- Oncolys to Set Up US Subsidiary to Ratchet Up Licensing Activities
August 22, 2016
- Evidence for Actair Sublingual Tablets “Sets It Apart from Other Therapies”: Shionogi
August 22, 2016
- Oncolys, Kyoto Pref. University of Medicine to Study OBP-801 for Glaucoma
August 19, 2016
- Amgen Confident of Getting Handsome Slice of Japan Biosimilar Market: Exec
August 19, 2016
- CEO of Teva-Takeda JV Confident on Handling Both Long-Listed Brands, Generics
August 17, 2016
- Ethical Drug Sales Down 0.8% in June: Crecon Report
August 17, 2016
- Mitsubishi Tanabe to Focus on Sales Turnaround for Canaglu, Eyes Diabetes and Nephrology Sales of 100 Bil. Yen
August 17, 2016
- Taiho Phama Subsidiary Gets Approval for Uzel AG
August 16, 2016
- Japan NDA Filed for Gilead’s HIV Drug Descovy
August 16, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…